Comparison. Research use only.
AOD-9604 vs 5-Amino-1MQ
Both are studied in metabolic and adipose-tissue research, and neither is what it is often marketed as. AOD-9604 is a growth-hormone fragment whose clinical obesity program failed its Phase IIb endpoint. 5-Amino-1MQ is not a peptide at all but a small-molecule NNMT inhibitor, with a literature that remains entirely preclinical.
AOD-9604
AOD-9604 is a synthetic hexadecapeptide, a 16-amino-acid chain, corresponding to the C-terminal fat-mobilizing (lipolytic) domain of human growth hormone, residues 177-191, with an added N-terminal tyrosine and a disulfide bond between its two cysteines. It was developed on the hypothesis that the fat-mobilizing and anti-fat-storing activity of growth hormone can be separated from its growth-promoting (somatogenic) activity. That growth-promoting activity works through GH receptor dimerization and downstream JAK2/STAT5 signaling, which leads to hepatic IGF-1 production. Consistent with that separation, AOD-9604 does not compete for the growth hormone receptor, and it did not induce cell proliferation or raise IGF-1 in the systems studied. In rodents it also did not reproduce the hyperglycemia and insulin resistance seen with full-length growth hormone. In obese rodent models, chronic administration reduced body weight gain and increased whole-body fat oxidation, and was associated with increased adipose beta-3 adrenergic receptor expression. Importantly, the frequently repeated claim that AOD-9604 acts through beta-3 adrenergic receptor agonism is contradicted by the primary literature. Heffernan and colleagues tested the peptide in beta-3 adrenergic receptor knockout mice and concluded that the lipolytic actions of both growth hormone and AOD-9604 are not mediated directly through that receptor. The precise molecular target behind the rodent lipolytic effect has not been definitively established. In anti-doping metabolism work the parent peptide is rapidly degraded, with a shorter fragment identified as a comparatively stable metabolite.
5-Amino-1MQ
5-Amino-1MQ is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic methyltransferase that moves a methyl group from S-adenosylmethionine onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. It is not a peptide. Nicotinamide is also the starting material for the NAD+ salvage pathway via NAMPT, so high NNMT activity pulls nicotinamide away from NAD+ regeneration while consuming S-adenosylmethionine at the same time. That places the enzyme at the intersection of cellular NAD+ availability and methylation capacity. Expression of the enzyme is markedly elevated in white adipose tissue and liver in obesity, which provided the rationale for inhibiting it. 5-Amino-1MQ is a quinolinium (a permanently charged cation), and getting such a molecule across the cell membrane was the principal medicinal-chemistry obstacle for this compound class. The reported advance of the methylquinolinium series was achieving access to the cell interior despite that charge. Neelakantan and colleagues characterized the compound as an analog from their initial inhibitor series, with a half-maximal inhibitory concentration of approximately 1 micromolar against the enzyme. Downstream effects reported in treated adipocytes and mouse tissue are consistent with restored nicotinamide and NAD+ pools and increased methylation-dependent flux, together with changes in sirtuin-dependent signaling and polyamine metabolism. A substantial fraction of the inhibitor literature, including several frequently cited metabolic papers, used other compounds in the series or structurally unrelated inhibitors. Those results should not be attributed to 5-Amino-1MQ specifically.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →